Back to Authors

Richardson, PG

A5001463711 | I4210117453

Mayo Clinic

Dana-Farber Cancer Institute

Citations 4

P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 855-856

10.1097/01.hs9.0000846728.05693.f8

P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 858-859

10.1097/01.hs9.0000846740.75414.50

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 18-18

10.1097/01.hs9.0000829624.40467.0d

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 14-15

10.1097/01.hs9.0000829600.37424.88